Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.91 USD
−71.58 M USD
0.00 USD
30.85 M
About Enliven Therapeutics, Inc.
Sector
Industry
CEO
Samuel S. Kintz
Website
Headquarters
Boulder
Founded
2019
FIGI
BBG00CP3BDD4
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ELVN is 22.47 USD — it has decreased by −1.75% in the past 24 hours. Watch Enliven Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Enliven Therapeutics, Inc. stocks are traded under the ticker ELVN.
ELVN stock has fallen by −3.10% compared to the previous week, the month change is a −14.40% fall, over the last year Enliven Therapeutics, Inc. has showed a 82.09% increase.
We've gathered analysts' opinions on Enliven Therapeutics, Inc. future price: according to them, ELVN price has a max estimate of 42.00 USD and a min estimate of 33.00 USD. Watch ELVN chart and read a more detailed Enliven Therapeutics, Inc. stock forecast: see what analysts think of Enliven Therapeutics, Inc. and suggest that you do with its stocks.
ELVN reached its all-time high on Jun 9, 2020 with the price of 250.84 USD, and its all-time low was 3.90 USD and was reached on Apr 13, 2022. View more price dynamics on ELVN chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ELVN stock is 5.31% volatile and has beta coefficient of 2.41. Track Enliven Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Enliven Therapeutics, Inc. there?
Today Enliven Therapeutics, Inc. has the market capitalization of 1.10 B, it has increased by 1.29% over the last week.
Yes, you can track Enliven Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Enliven Therapeutics, Inc. is going to release the next earnings report on Mar 13, 2025. Keep track of upcoming events with our Earnings Calendar.
ELVN earnings for the last quarter are −0.48 USD per share, whereas the estimation was −0.50 USD resulting in a 3.41% surprise. The estimated earnings for the next quarter are −0.51 USD per share. See more details about Enliven Therapeutics, Inc. earnings.
Enliven Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
ELVN net income for the last quarter is −23.16 M USD, while the quarter before that showed −19.95 M USD of net income which accounts for −16.07% change. Track more Enliven Therapeutics, Inc. financial stats to get the full picture.
No, ELVN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 46.00 employees. See our rating of the largest employees — is Enliven Therapeutics, Inc. on this list?
Like other stocks, ELVN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Enliven Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Enliven Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Enliven Therapeutics, Inc. stock shows the neutral signal. See more of Enliven Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.